Literature DB >> 9877106

Glomerular filtration rate measurement in cirrhotic patients with renal failure.

L Roy1, L Legault, G Pomier-Layrargues.   

Abstract

Assessment of renal function, namely glomerular filtration rate (GFR), by the renal creatinine clearance, may be problematic and less accurate in cirrhotics; however, it is an essential element in the global evaluation of these patients. In order to better characterize misinterpretation of GFR by the renal creatinine clearance, we compared a group of cirrhotic patients with renal failure (n - 30) to a group of chronic renal failure patients (CRF) without liver disease (n - 5). Inulin and PAH clearances were measured during a 4-hour infusion of inulin and PAH; renal creatinine clearance was measured during a 24-hour urine collection and this, simultaneously with inulin and PAH clearance. We observed that in moderate to severe renal failure (renal inulin clearance 30 +/- 10 ml/min), GFR (i. e. renal inulin clearance) in cirrhotic patients was overestimated by the renal creatinine clearance, similarly to CRF patients (ratio 1.8 +/- 0.7 and 1.6 +/- 0.9 respectively); however cirrhotic patients have a lower serum creatinine (186 +/- 97 vs 133 +/- 62 micromol/l respectively). On the other hand, cirrhotic patients with mild renal dysfunction (renal inulin clearance 74 +/- 15 ml/min) had a renal creatinine clearance of 77 +/- 25 ml/min. Systemic inulin clearance overestimated renal inulin clearance, proportionally to the severity of renal dysfunction. We conclude that it is only the degree of renal failure, irrespective of etiology, that explains the overestimation of the glomerular filtration rate by the renal creatinine clearance in cirrhotic patients; hence, there is no specific alteration in the renal excretion of creatinine in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877106

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

Review 1.  GFR Estimating Equations and Liver Disease.

Authors:  Tomasz Beben; Dena E Rifkin
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

2.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 3.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Serum sodium, renal function, and survival of patients with end-stage liver disease.

Authors:  Young-Suk Lim; Timothy S Larson; Joanne T Benson; Patrick S Kamath; Walter K Kremers; Terry M Therneau; W Ray Kim
Journal:  J Hepatol       Date:  2010-02-04       Impact factor: 25.083

Review 5.  Evaluation of renal function in patients with cirrhosis: where are we now?

Authors:  Nicolas Rognant; Sandrine Lemoine
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 6.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

Review 7.  Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Mitra K Nadim; John A Kellum; Andrew Davenport; Florence Wong; Connie Davis; Neesh Pannu; Ashita Tolwani; Rinaldo Bellomo; Yuri S Genyk
Journal:  Crit Care       Date:  2012-02-09       Impact factor: 9.097

8.  Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels.

Authors:  Dong Jin Kim; Hyun Seok Kang; Hyuk Soon Choi; Hye Jin Cho; Eun Sun Kim; Bora Keum; Hyonggin An; Ji Hoon Kim; Yeon Seok Seo; Yong Sik Kim; Hyung Joon Yim; Yoon Tae Jeen; Hong Sik Lee; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu
Journal:  Korean J Hepatol       Date:  2011-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.